paediatrics Brussels 17

Phase II trial of selumetinib in patients with recurrent/progressive LGG.

25 patients with NF-1 enrolled on stratum 3, there were 10 PR, 14 SD and 1 PD while the patients were on treatment.

No visual assessments

The 2 year PFS for stratum 3 was 96+4%.

(Personal communication Fangusaro and Onar-Thomas, 2017).